General Clinical Chemistry Analyzers and Accessories
Abcam Ispinesib (SB-715992), 100MG
MW 517.1 Da, Purity >98%. A potent, selective and reversible allosteric inhibitor of KSP with IC₅₀ value of 0.5 nM. Often combines with chemotherapy drugs to tumor treatment.
The product is subject to the following: Abcam Restricted Use Statement
GENERAL BIOPHYSICS LLC Helium Gas Analyzer Model A
Thermoconductivity Gas Analyzer for Helium with Onboard PumpApplication: Calibrated for argon gas with onboard pump to take gas samples.Features: Includes data display screen.Accuracy: ±0.1%.
Abcam LY2874455, FGF/FGFR inhibitor, 25MG
MW 444.3 Da, Purity >98%. Potent FGF/FGFR inhibitor. Inhibits in vitro autophosphorylation of FGFR-1, FGFR-2, FGFR-3, and FGFR-4 with similar inhibition potency for all four FGFRs (IC₅₀ < 6.4 nM). Exhibits a 6- to 9-fold in vitro and in vivo selectivity on inhibition of FGF- over VEGF-mediated target signaling in mice.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Furamidine dihydrochloride, 25MG
MW 304.3 Da, Purity >=98%. A potent, selective and cell-permeable protein arginine methyltransferase 1 (PRMT1) inhibitor (IC₅₀ = 9.4 μM). Displays selectivity over PRMT5, PRMT6 and CARM1 (IC₅₀ values are 166, 283 and >400 μM respectively). Inhibits cell proliferation in leukemia cell lines.
The product is subject to the following: Abcam Restricted Use Statement
Abcam IO x 2, HIF-1alpha prolyl hydro x ylase-2 (PHD2) inhibitor, 25MG
MW 352.3 Da, Purity >98%. Potent, cell-permeable, selective HIF-1α prolyl hydroxylase-2 (PHD2) inhibitor (IC₅₀ = 21 nM). Displays over 100-fold selectivity for PHD2 over factor inhibiting HIF-1 (FIH-1) and histone demethylases JMJD2A, JMJD2C, JMJD2E and JMJD3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LM22A-4, neurotrophic BDNF mimetic, 50MG
MW 339.34 Da, Purity >98%. Small molecule BDNF mimetic displaying neurotrophic activity. Partial agonist at TrkB, activating TrkB signaling. Displaces BDNF (IC₅₀ = 47 nM) in binding assays. Prevents neuronal degeneration with equal efficacy to that of BDNF in in vitro models of neurodegenerative disease. Causes hippocampal and striatal TrkB activation in mice and improved motor learning after traumatic brain injury in rats, after in vivo administraton. Improves respiratory function in a mouse model of Rett syndrome.
The product is subject to the following: Abcam Restricted Use Statement
Abcam URMC-099, 5MG
MW 421.5 Da, Purity >98%. Novel orally bioavailable, brain penetrant mixed lineage kinase (MLK) inhibitor (IC₅₀ values of 19, 42, 14, and 150 nM for MLK1, MLK2, MLK3, and the related MLK family member DLK, respectively). Inhibits multiple kinase pathways including LRRK2 (IC₅₀ = 11 nM). Decreases the production of inflammatory cytokines in cultured microglia exposed to HIV-1 Tat. Reduces fMLP-induced chemotaxis of neutrophil from wild-type C57Bl/6 mice. Facilitates Amyloid-β Clearance in a Murine Model of Alzheimer's Disease.
The product is subject to the following: Abcam Restricted Use Statement
Hach Company CLT10sc Total CL Analyzer
CLT10sc Total Chlorine AnalyzerIncludes CL10 sc Panel-1 m digital extension cable-Panel Manual-Chlorine Sensor Manual
Abcam BAY-299, TAF1 and BRD1 inhibitor, 25MG
MW 429.5 Da, Purity >98%. Potent and selective bromodomain inhibitor of TAF1 (IC₅₀ = 8-13 nM) and BRD1 (IC₅₀ = 6-67 nM). More than 30-fold selective versus BRD9 and ATAD2. More than 300-fold selective versus BRD4. Inhibits BRD1 (IC₅₀ = 0.58 μM) and TAF1 (IC₅₀ = 0.9 μM) binding to Histone H4 in cell-based assays; also inhibits BRD1 (IC₅₀ = 0.83 μM) and TAF1 (IC₅₀ = 1.4 μM) binding to Histone H3.3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam TC 14012, Peptidomimetic C x CR4 antagonist, 10MG
MW 2066.4 Da, Purity >95%. TC 14012, Peptidomimetic CXCR4 antagonist. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LY2940680 (Taladegib), 50MG
MW 512.5 Da. Potent Hedgehog signaling pathway inhibitor. Smoothened antagonist. Inhibits growth of cancer cell lines containing a disease-relevant Smoothened gene mutation. Has anti-tumor activity in animal models.
The product is subject to the following: Abcam Restricted Use Statement